Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

This success suggests that the complex interactions between therapeutic cells and their targets could lead to innovative treatments for both autoimmune diseases and cancer. Initial trials using CAR T ...

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

People living with the disease have been given hope of lifelong relief by a new cell therapy which has had successful results ...

As the new year is here, take a look at some of the most common New Year's resolutions, with tips on how to follow through ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with ...

BMW’s electric future is taking shape on the outskirts of the Mexican city of San Luis Potosi, some 450 miles south of the ...

Cellectis has deprioritized one of its leukemia-focused candidates in order to focus on its other two clinical-stage CAR-T therapies. | Cellectis has deprioritized one of its leukemia-focused ...

A battery pack manufacturer has released a new solution for Tesla Roadster with aging battery packs. It would slash ...

A growing body of research suggests that clinicians can offer chimeric antigen receptor (CAR) T-cell therapy safely and ...